Study on ligustrazine combined with chemotherapy in patients with relapsed or refractory non-Hodgkin's lymphoma
10.3760/cma.j.issn.1673-422X.2010.05.023
- VernacularTitle:川芎嗪联合化疗对复发或耐药非霍奇金淋巴瘤的研究
- Author:
Qiao JIANG
;
Xigui YANG
- Publication Type:Journal Article
- Keywords:
Lymphoma,non-hodgkin;
Drug resistance;
Ligustrazine;
Drug therapy,combination
- From:
Journal of International Oncology
2010;37(5):397-400
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the efficacy of ligustrazine combined with chemotherapy in patients with relapsed or refractory NHL and the relationships with P-gp expression. Methods 60 Patients were randomized into reversal agent group (ligustrazine + chemotherapy) and control group (chemotherapy) and the outcome was analysed. P- gp expression was analysed by flow cytometry. Subgroup analysis was conducted a ccording to P-gp expression. Results 56 patients could be evaluated. Progression -free survival (PFS) showed no statistical diference in two groups ( P = 0.065 1 ) ; reversal agent group had a higher overall response rate (ORR) than control group(P=0. 048).Subgroup analysis showed 41 patients had P-gp( +). The complete remission rate and complete remission uncertain rate of patients with P-gp( + ) in reversal agent group and control group were 33. 33% and 8. 70% , respectively, reversal agent group had a significant advantage ( P = 0. 048). Patients with P-gp( + ) in reversal agent group had a higher ORR than control group (61. 11% vs 26. 09% ,P =0.024). Kaplan-Meier survival curve and Log-rank test showed patients with P-gp( + ) in reversal agent group had longer PFS than control group (P =0.046 4). Blood pressure in a small number of patients received ligustrazine therapy decreased,and mitigated after reducing the dose. Conclusion Ligustrazine combined with chemotherapy can elevate response rate,prolong PFS with manageable toxicity and correlate to P-gp expression in relapsed or refractory NHL
